APTORUM GROUP LTD-CLASS A (APM) Stock Price & Overview
NASDAQ:APM • KYG6096M1226
Current stock price
The current stock price of APM is 0.8801 USD. Today APM is up by 0.58%. In the past month the price decreased by -4.88%. In the past year, price decreased by -5.37%.
APM Key Statistics
- Market Cap
- 7.164M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.35
- Dividend Yield
- N/A
APM Stock Performance
APM Stock Chart
APM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to APM. When comparing the yearly performance of all stocks, APM is a bad performer in the overall market: 77.2% of all stocks are doing better.
APM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to APM. Both the profitability and financial health of APM have multiple concerns.
APM Earnings
APM Forecast & Estimates
APM Financial Highlights
Over the last trailing twelve months APM reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS decreased by -2109.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.41% | ||
| ROE | -8.93% | ||
| Debt/Equity | 0.15 |
APM Ownership
APM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About APM
Company Profile
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
Company Info
IPO: 2018-12-18
APTORUM GROUP LTD-CLASS A
17 Hanover Square
London W1S 1BN GB
CEO: Ian Huen
Employees: 1
Phone: 85239537700
APTORUM GROUP LTD-CLASS A / APM FAQ
What does APM do?
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
What is the stock price of APTORUM GROUP LTD-CLASS A today?
The current stock price of APM is 0.8801 USD. The price increased by 0.58% in the last trading session.
What is the dividend status of APTORUM GROUP LTD-CLASS A?
APM does not pay a dividend.
What is the ChartMill technical and fundamental rating of APM stock?
APM has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in APTORUM GROUP LTD-CLASS A be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on APM.
What is the expected growth for APM stock?
The Revenue of APTORUM GROUP LTD-CLASS A (APM) is expected to decline by -26.52% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of APTORUM GROUP LTD-CLASS A (APM) stock?
The outstanding short interest for APTORUM GROUP LTD-CLASS A (APM) is 0.22% of its float.